[Small Cell Lung Cancer Advanced Treatment] New Pathway to Extending Survival: Clinical Evidence of Topotecan Combined with Berzosertib in Recurrent Small Cell Lung Cancer

[Small Cell Lung Cancer Advanced Treatment] Topotecan Combined with Berzosertib: Precisely Targeting Cancer Cell Repair Mechanisms

Small cell lung cancer (SCLC) upon recurrence typically shows rapidly declining treatment response and poor prognosis. The conventional chemotherapy drug Topotecan (topotecan hydrochloride) is standard second-line treatment, but efficacy remains significantly limited. A Phase 2 clinical trial published in JAMA Oncology brings new hope to recurrent patients: by adding the ATR inhibitor Berzosertib, it effectively enhances drug potency and extends survival.

I. Clinical Trial: Breakthrough in Survival Benefit

This trial randomly assigned 60 previously treated recurrent small cell lung cancer patients to either "Topotecan monotherapy" or "Topotecan + Berzosertib" combination groups.

Core Clinical Data:

• Overall Survival (OS): The median OS in the combination group significantly improved to 8.9 months, substantially better than the monotherapy group's 5.4 months.
• Progression-Free Survival (PFS): While no statistically significant difference existed between groups (3.9 months vs. 3.0 months), the significant extension in survival time demonstrates the long-term value of combination therapy in controlling disease progression.
• Mechanism of Action: Berzosertib, as an ATR inhibitor, blocks cancer cells' ability to repair damaged DNA, making chemotherapy attacks more lethal.

II. Safety and Adverse Event Management

While combination therapy improves efficacy, its adverse event profile receives considerable attention:

• Common Reactions: Primarily hematologic toxicity (such as neutropenia and thrombocytopenia) and gastrointestinal reactions (vomiting).
• Clinical Monitoring: Japanese physicians carefully monitor blood count changes when applying such "sensitization schemes" and provide G-CSF (granulocyte-colony stimulating factor) support as needed to ensure treatment continuity.

III. Medical Team's Comprehensive Recommendations

The key to small cell lung cancer treatment lies in "precision" and "combination." Leading Japanese hospitals have begun conducting in-depth research into DNA repair pathways when managing recurrent cases. Medical Supporter's team continuously monitors these cutting-edge combination strategies integrating targeted therapy with chemotherapy, working to seize every opportunity for patients.

Medical Supporter: Your Advanced Lung Cancer Treatment Partner

Facing recurrent small cell lung cancer, time is the patient's most valuable resource. If you are seeking advanced combination approaches beyond standard chemotherapy, Medical Supporter's team can connect you with Japanese lung cancer authorities with extensive clinical research credentials, providing cutting-edge treatment recommendations and comprehensive support for medical care in Japan.

Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4